Novo Nordisk Keeps Buying Back Its Own Stock While Its Growth Story Remains Unsettled
Published on 11/17/2026 at 06:11 | Editorial boerse-global.deNovo Nordisk's latest disclosure to the market is a reminder that a share buyback is a capital-return tool, not a verdict on the business. Over the past week the Danish drugmaker repurchased 1,130,000 B shares for a total of DKK 310,059,558, extending a programme that has been running since 4 February.
Cumulatively, the company has now bought back 43,734,179 B shares worth DKK 12,118,073,269. The framework allows for up to DKK 15 billion of repurchases across twelve months, and following the most recent transactions Novo Nordisk held treasury B shares equal to 1.3% of its share capital. Nothing in today's announcement points to a newly resolved expansion of the programme — it documents steady execution within an existing mandate. The company also reported a net reduction of its own shares under remuneration schemes, transfers that sit outside the buyback and should be assessed separately. No cancellation of the repurchased stock was announced.
A Raised Outlook That Still Includes Contraction
The buybacks are unfolding against a guidance range that cuts both ways. On 4 November Novo Nordisk lifted its full-year forecast, but for 2026 it still expects adjusted revenue and adjusted operating profit to move between ?2% and +2% at constant exchange rates. In other words, the upgraded outlook accommodates a decline just as readily as growth — a detail that keeps the capital-return story from doubling as evidence of an operational turnaround.
The third quarter of 2026 illustrates the split inside the company. Adjusted operating profit rose 27% at constant currencies to DKK 31.7 billion, yet obesity revenue climbed 22% while diabetes revenue fell 5%. Strength in one franchise is not offsetting weakness in the other, which means the durability of the buyback case rests partly on whether management can steady the broader operating trend. The higher guidance is an encouraging signal; it is not proof of a wide recovery.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
US List Prices Set to Fall
A concrete pricing factor looms over that question. From 1 January 2027, US list prices are set to drop by roughly 50% for Wegovy and roughly 35% for Ozempic. The percentages alone cannot tell investors how revenue and earnings will ultimately be affected, but they are a reason not to read the buyback in isolation as a buying signal.
Pediatric Data and Pipeline Readouts
On the clinical front, Novo Nordisk reported results from the STEP Young trial of Wegovy in children aged six to under twelve. According to the company, almost 80% of participants achieved a reduction in body-mass index of at least 10%, while no child in the placebo group reached that threshold.
The same day, at ObesityWeek, the group presented preclinical and human data suggesting that activation of amylin and calcitonin receptors could help preserve bone during weight loss. It also unveiled phase 3 results from REDEFINE 9 for the investigational candidate CagriSema in adults with overweight or obesity, published simultaneously in The Lancet Diabetes & Endocrinology. For two lower dose levels, estimated average weight loss came in at 20.7% and 21.0% respectively, assuming all participants continued treatment; under the same assumption, placebo produced 2.0%.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Denmark Expands Ozempic Reimbursement
Reimbursement rules in Novo's home market have shifted as well. Since 9 November, the 2 mg dose of Ozempic has qualified for general reimbursement with conditions. The Danish Medicines Agency said the decision followed confidential price negotiations.
Taken together, the picture is of a company returning capital on schedule while its growth trajectory — and the US pricing environment — remain the open questions that will ultimately determine what those repurchases are worth.
Ad
Novo Nordisk Stock: New Analysis - 17 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
